UCP2 expression may represent a predictive marker of neoadjuvant chemotherapy effectiveness for locally advanced uterine cervical cancer

Imai,Kenji; Fukuda,Takeshi; Wada,Takuma; Kawanishi,Masaru; Tasaka,Reiko; Yasui,Tomoyo; Sumi,Toshiyuki

doi:10.3892/ol.2017.6212

UCP2 expression may represent a predictive marker of neoadjuvant chemotherapy effectiveness for locally advanced uterine cervical cancer

Authors:
- Kenji Imai
- Takeshi Fukuda
- Takuma Wada
- Masaru Kawanishi
- Reiko Tasaka
- Tomoyo Yasui
- Toshiyuki Sumi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan
Published online on: May 19, 2017 https://doi.org/10.3892/ol.2017.6212
Pages: 951-957

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Concurrent chemoradiotherapy is the standard treatment for locally advanced uterine cervical cancer. However, effective neoadjuvant chemotherapy (NAC) can reduce tumor size and facilitate hysterectomy for locally advanced uterine cervical cancer. NAC treatment could improve the prognosis of patients with locally advanced cervical cancer. However, if NAC is ineffective, radiotherapy must be pursued. This causes a delay in initiating the core treatment and results in a worse prognosis. Therefore, the identification of predictive markers of whether NAC is likely to be effective for the treatment of locally advanced uterine cervical cancer could improve patient prognosis. Uncoupling protein 2 (UCP2) is broadly expressed in cancer cells, and suppresses mitochondrial reactive oxygen species (ROS) production. UCP2 contributes to both carcinogenesis and chemoresistance by reducing ROS. Downregulation of UCP2 results in significantly increased cell death following chemotherapy. The present study investigated the association between UCP2 expression and NAC effectiveness. A total of 58 patients with locally advanced uterine cervical cancer (stage IIIA or IIIB) treated at Osaka City University Hospital between April 1995 and March 2010 were examined. Tumor tissue samples were obtained by punch biopsy prior to NAC. UCP2 expression was examined immunohistochemically and scored using a weighted scoring system. Patients were divided into NAC effective (n=34) and ineffective (n=24) groups. Furthermore, UCP2 expression in human uterine cervical cancer cells was inhibited by genipin, and changes in cisplatin sensitivity were examined. UCP2 weighted score was higher in the NAC ineffective group than in the NAC effective group (P=0.038). Additionally, the low UCP2 expression group was more sensitive to NAC than the high UCP2 expression group (P=0.041). Sensitivity to cisplatin was significantly increased when UCP2 was inhibited in human uterine cervical cancer cells in vitro. UCP2 expression may become a predictive marker of whether NAC is effective for patients with locally advanced uterine cervical cancer, which could improve patient prognosis.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
3	Ebina Y, Yaegashi N, Katabuchi H, Nagase S, Udagawa Y, Hachisuga T, Saito T, Mikami M, Aoki Y and Yoshikawa H: Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer. Int J Clin Oncol. 20:240–248. 2015. View Article : Google Scholar : PubMed/NCBI
4	National comprehensive cancer network, . NCCN clinical practice guidelines in oncology-cervical cancer-version II. 2013.
5	Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
6	Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol. 22:872–880. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ishiko O, Sumi T, Yasui T, Matsumoto Y, Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R: Balloon-occluded arterial infusion chemotherapy, simple total hysterectomy, and radiotherapy as a useful combination-therapy for advanced cancer of the uterine cervix. Oncol Rep. 7:141–144. 2000.PubMed/NCBI
8	Souhami L, Gil RA, Allan SE, Canary PC, Araújo CM, Pinto LH and Silveira TR: A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol. 9:970–977. 1991. View Article : Google Scholar : PubMed/NCBI
9	Tattersall MH, Lorvidhaya V, Vootiprux V, Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A, Yen MS, et al: Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical cancer study group of the Asian Oceanian clinical oncology association. J Clin Oncol. 13:444–451. 1995. View Article : Google Scholar : PubMed/NCBI
10	Ishiko O, Sumi T, Yasui T, Matsumoto Y, Ogita S, Kaminou T, Nakamura K and Yamada R: Tumor marker and MR imaging criteria for evaluating the efficacy of cyclic balloon-occluded arterial infusion for advanced cancer of the uterine cervix. Oncol Rep. 7:827–830. 2000.PubMed/NCBI
11	Ishiko O, Sumi T, Yoshida H, Ogita S and Yamada R: Expression of apoptosis regulatory proteins in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion chemotherapy. Int J Oncol. 18:1151–1155. 2001.PubMed/NCBI
12	Okamoto E, Sumi T, Misugi F, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K and Ishiko O: Expression of apoptosis-related proteins in advanced uterine cervical cancer after balloon-occluded arterial infusion chemotherapy as an indicator of the efficiency of this therapy. Int J Mol Med. 15:41–47. 2005.PubMed/NCBI
13	Nobeyama H, Sumi T, Misugi F, Okamoto E, Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K and Ishiko O: Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer. Int J Mol Med. 14:101–105. 2004.PubMed/NCBI
14	Panici P Benedetti, Bellati F, Manci N, Pernice M, Plotti F, Di Donato V, Calcagno M, Zullo MA, Muzii L and Angioli R: Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer. Ann Surg Oncol. 14:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
15	Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 7:97–110. 2004. View Article : Google Scholar : PubMed/NCBI
16	Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, Weill B and Goldwasser F: Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer. 119:41–48. 2006. View Article : Google Scholar : PubMed/NCBI
17	Fruehauf JP and Meyskens FL Jr: Reactive oxygen species: A breath of life or death? Clin Cancer Res. 13:789–794. 2007. View Article : Google Scholar : PubMed/NCBI
18	Boss O, Muzzin P and Giacobino JP: The uncoupling proteins, a review. Eur J Endocrinol. 139:1–9. 1998. View Article : Google Scholar : PubMed/NCBI
19	Fleury C and Sanchis D: The mitochondrial uncoupling protein-2: Current status. Int J Biochem Cell Biol. 31:1261–1278. 1999. View Article : Google Scholar : PubMed/NCBI
20	Baffy G: Uncoupling protein-2 and cancer. Mitochondrion. 10:243–252. 2010. View Article : Google Scholar : PubMed/NCBI
21	Echtay KS, Murphy MP, Smith RA, Talbot DA and Brand MD: Superoxide activates mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted antioxidants. J Biol Chem. 277:47129–47135. 2002. View Article : Google Scholar : PubMed/NCBI
22	Hoang T, Smith MD and Jelokhani-Niaraki M: Toward understanding the mechanism of ion transport activity of neuronal uncoupling proteins UCP2, UCP4, and UCP5. Biochemistry. 51:4004–4014. 2012. View Article : Google Scholar : PubMed/NCBI
23	Carretero MV, Torres L, Latasa U, Garcia-Trevijano ER, Prieto J, Mato JM and Avila MA: Transformed but not normal hepatocytes express UCP2. FEBS Lett. 439:55–58. 1998. View Article : Google Scholar : PubMed/NCBI
24	Horimoto M, Resnick MB, Konkin TA, Routhier J, Wands JR and Baffy G: Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res. 10:6203–6207. 2004. View Article : Google Scholar : PubMed/NCBI
25	Duval C, Nègre-Salvayre A, Dogilo A, Salvayre R, Pénicaud L and Casteilla L: Increased reactive oxygen species production with antisense oligonucleotides directed against uncoupling protein 2 in murine endothelial cells. Biochem Cell Biol. 80:757–764. 2002. View Article : Google Scholar : PubMed/NCBI
26	Mattiasson G, Shamloo M, Gido G, Mathi K, Tomasevic G, Yi S, Warden CH, Castilho RF, Melcher T, Gonzalez-Zulueta M, et al: Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med. 9:1062–1068. 2003. View Article : Google Scholar : PubMed/NCBI
27	Teshima Y, Akao M, Jones SP and Marbán E: Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. Circ Res. 93:192–200. 2003. View Article : Google Scholar : PubMed/NCBI
28	Pozza E Dalla, Fiorini C, Dando I, Menegazzi M, Sgarbossa A, Costanzo C, Palmieri M and Donadelli M: Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine. Biochim Biophys Acta. 1823:1856–1863. 2012. View Article : Google Scholar : PubMed/NCBI
29	Mailloux RJ, Adjeitey CN and Harper ME: Genipin-induced inhibition of uncoupling protein-2 sensitizes drug-resistant cancer cells to cytotoxic agents. PLoS One. 5:e132892010. View Article : Google Scholar : PubMed/NCBI
30	Derdák Z, Fülöp P, Sabo E, Tavares R, Berthiaume EP, Resnick MB, Paragh G, Wands JR and Baffy G: Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. Carcinogenesis. 27:956–961. 2006. View Article : Google Scholar : PubMed/NCBI
31	Tsuji K, Yamada R, Kawabata M, Mitsuzane K, Sato M, Iwahashi M, Kitayama S and Nakano R: Effect of balloon occluded arterial infusion of anticancer drugs on the prognosis of cervical cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 32:1337–1345. 1995. View Article : Google Scholar : PubMed/NCBI
32	Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
33	Collins P, Jones C, Choudhury S, Damelin L and Hodgson H: Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. Liver Int. 25:880–887. 2005. View Article : Google Scholar : PubMed/NCBI
34	Pozza E Dalla, Fiorini C, Dando I, Menegazzi M, Sgarbossa A, Costanzo C, Palmieri M and Donadelli M: Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine. Biochim Biophy Acta. 1823:1856–1863. 2012. View Article : Google Scholar